WHY ARE MEDTRONIC THERAPIES DIFFERENT?

COMMUNICATION IS CRITICAL

Evidence suggests that breakdowns in the bladder-brain communication pathway are the root cause of OAB and non-obstructive urinary retention.3-5 While other therapies focus on the bladder muscles, Medtronic therapies target the nerves, which is thought to help restore normal bladder function.*

Graphic depicting brain and urinary system communication

MEDTRONIC BLADDER CONTROL THERAPY DELIVERED BY THE INTERSTIM™ SYSTEM

Medtronic InterStim II System next to a quarter to represent size.

THE RELIEF YOU’VE BEEN WAITING FOR

  • Targets the nerves that control your bladder to help it function normally again
  • 85% of OAB patients using it achieved success in the first year6‡
  • 3X greater improvements in quality of life compared to medications7
  • Only therapy that lets you see if it works before you and your doctor decide
  • More than 225,000 patients have received relief as a safe, FDA-approved and minimally invasive bladder or bowel control therapy

Implanting an InterStim™ system has risks similar to any surgical procedure, including swelling, bruising, bleeding, and infection. Talk with your doctor about ways to minimize these risks.

LASTING RELIEF, AT LAST

Abdominal cross section showing the urinary and digestive systems

Medtronic bladder control therapy delivered by the InterStimTM system provides life-changing relief.

  • 84% satisfaction among OAB patients who use it8
  • 76% of people achieved success at 6 months compared to 49% who used
  • medications7,‡
  • The only OAB therapy that provides better relief than medications7,9,10

The most common adverse events experienced during clinical studies included pain at implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations. Any of these may require additional surgery or cause return of symptoms.

Are you Ready?

Answer a few quick questions to see if you qualify for treatment.

Take the quiz

TALK TO A SPECIALIST

Speak with a doctor in your community who can help you find the right treatment.

FIND A SPECIALIST

DISCOVER WHAT RELIEF LOOKS LIKE

Get our e-newsletter for success stories and tips for managing and treating your condition.

SIGN UP NOW

REAL PEOPLE, REAL RELIEF

Hear from people who have successfully reduced their symptoms with help from Medtronic bladder control therapy.

READ PATIENT STORIES

START YOUR JOURNEY

Bladder control problems affect millions of people. But relief is closer than you think.

SEE THE STEPS

MEDTRONIC BLADDER CONTROL THERAPY DELIVERED BY THE NURO™ SYSTEM

NURO DEVICE

REGAIN YOUR FREEDOM

  • Targets the tibial nerve to help you regain control of your bladder
  • Does not cause unpleasant side effects like many oral medications can10 ||
  • Does not require self-catheterization, unlike injectable medications9
  • Helps you live with less worry and more confidence1

The NURO™ system only treats the symptoms of OAB, not urinary retention. Most common side effects of PTNM are temporary and include mild pain or skin inflammation at or near the stimulation site.

VIEW MORE DETAILS

START THE CONVERSATION

Talking about bladder control problems can be difficult. But this doctor discussion guide can help you get through it more easily.

GET THE GUIDE

WHAT IS BLADDER CONTROL THERAPY?

Read a quick overview to understand your options and see if Medtronic bladder control therapy might be right for you.

READ THE BROCHURE

VISUALIZE YOUR JOURNEY

The care pathway helps you understand all of the treatment options available for bladder control problems.

DOWNLOAD THE PATHWAY
*

Restored bladder function is defined as a 50% or greater reduction in your troublesome bladder symptoms.

Success defined as a 50% or greater reduction in your troublesome bladder symptoms.

Numbers reflect completers analysis defined as patients with diary data at baseline and 12 months (n=220). Clinical success was 82% at 12 months using the modified completers analysis (subjects who either had a baseline and 12 month evaluation or withdrew early due to device-related reasons and are considered failures). Success defined as a 50% or greater reduction in your troublesome bladder symptoms.

§

These patient groups were analyzed based on the treatment they were assigned: incomplete data was counted as ”failures.” Another analysis reported 61% of people achieved success with InterStim, compared to 42% who used medications.

||

While the NURO™ device was not used in these studies, since it delivers equivalent stimulation therapy as the device used in the studies, a user can expect similar performance.

1

Kobashi K, Nitti V, Margolis E, et al.  A prospective study to evaluate efficacy using the NURO percutaneous neuromodulation system in drug naive patients with overactive bladder syndrome. Urology 2019; 131: 77-82.

2

Siegel S, Noblett K, Mangel J, et al. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation. J Urol. 2018 Jan;199(1):229-236.

3

Dasgupta R. Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral Neuromodulation for urinary retention. J Urol. 2005;174:2268–2272

4

Griffiths D, Derbyshire S, Stenger A, Resnick N. Brain control of normal and overactive bladder. J Urol. 2005;174:1862–1867.

5

Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn. 2008;27(6):466–474.

6

Noblett K, Siegel S, Mangel J, et al. Results of a Prospective, Multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn. 2016 Feb;35(2):246-51.

7

Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim® Therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34:224–230. DOI: 10.1002/nau.22544.

8

Foster RT Sr, Anoia EJ, Webster GD, Amundsen CL. In patients undergoing neuromodulation for intractable urge incontinence a reduction in 24-hr pad weight after the initial test stimulation best predicts long-term patient satisfaction. Neurourol Urodyn. 2007;26:213–217.

9

Visco A, Brubaker L, Richter HE et al. Anticholinergic Therapy vs. OnabotulinumtoxinA for Urgency Urinary Incontinence. New Engl J Med. 2012;367(19):1803–1813.

10

Peters KM, MacDiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055–1061. 

Information on this site should not be used as a substitute for talking with your doctor. Always talk with your doctor about diagnosis and treatment information.